Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.

Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ.

Biol Psychiatry. 2013 Mar 15;73(6):501-9. doi: 10.1016/j.biopsych.2012.09.012. Epub 2012 Nov 7.

2.

SAR studies on mGlu5 receptor positive allosteric modulators (2003- 2013).

Hao J, Xiong H.

Curr Top Med Chem. 2014;14(15):1789-841. Review.

PMID:
25176124
3.

Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004-2012).

Lindsley CW, Stauffer SR.

Pharm Pat Anal. 2013 Jan;2(1):93-108. doi: 10.4155/ppa.12.82. Review.

PMID:
24236973
4.

Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.

Kanuma K, Aoki T, Shimazaki Y.

Recent Pat CNS Drug Discov. 2010 Jan;5(1):23-34. Review.

PMID:
19832691
5.

Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Stauffer SR.

ACS Chem Neurosci. 2011 Aug 17;2(8):450-70. doi: 10.1021/cn2000519. Epub 2011 Jun 27. Review.

6.

Identification of a Selective Allosteric Agonist of mGlu5.

Manka J, Zhou Y, Chun A, Dawson ES, Vinson PN, Niswender CM, Noetzel MJ, Rook JM, Bridges TM, Daniels JS, Jones C, Conn PJ, Lindsley CW, Stauffer SR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Dec 16 [updated 2013 Mar 7].

7.

Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.

Johnson MP, Nisenbaum ES, Large TH, Emkey R, Baez M, Kingston AE.

Biochem Soc Trans. 2004 Nov;32(Pt 5):881-7. Review.

PMID:
15494040
8.

Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.

Walker AG, Conn PJ.

Curr Opin Pharmacol. 2015 Feb;20:40-5. doi: 10.1016/j.coph.2014.11.003. Epub 2014 Nov 27. Review.

9.

The new compound GET73, N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide, Regulates hippocampal Aminoacidergic transmission possibly via an allosteric modulation of mGlu5 receptor. Behavioural evidence of its "anti-alcohol" and anxiolytic properties.

Ferraro L, Loche A, Beggiato S, Tomasini MC, Antonelli T, Colombo G, Lobina C, Carai MA, Porcu A, Castelli MP, Clerici F, Borelli AC, Cacciaglia R, Tanganelli S.

Curr Med Chem. 2013;20(27):3339-57. Review.

PMID:
23862615
10.
11.

Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.

Lundström L, Bissantz C, Beck J, Dellenbach M, Woltering TJ, Wichmann J, Gatti S.

Neuropharmacology. 2016 Dec;111:253-265. doi: 10.1016/j.neuropharm.2016.08.032. Epub 2016 Aug 30. Review.

PMID:
27590915
12.

Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2.

Lundström L, Bissantz C, Beck J, Dellenbach M, Woltering TJ, Wichmann J, Gatti S.

Neuropharmacology. 2017 Feb 16. pii: S0028-3908(17)30050-3. doi: 10.1016/j.neuropharm.2016.08.040. [Epub ahead of print] Review.

PMID:
28216000
13.

Identification of a glycine sulfonamide based non-MPEP site positive allosteric potentiator (PAM) of mGlu5.

Rodriguez AL, Tarr JC, Zhou Y, Williams R, Gregory KJ, Bridges TM, Daniels JS, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Dec 17 [updated 2013 Mar 22].

14.
15.

Identification of a high affinity MPEP-site silent allosteric modulator (SAM) for the metabotropic glutamate subtype 5 receptor (mGlu5).

Gregory KJ, Malosh C, Turlington M, Morrison R, Vinson P, Daniels JS, Jones C, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2013 Apr 15 [updated 2015 Feb 11].

16.

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.

Fell MJ, McKinzie DL, Monn JA, Svensson KA.

Neuropharmacology. 2012 Mar;62(3):1473-83. doi: 10.1016/j.neuropharm.2011.06.007. Epub 2011 Jun 21. Review.

PMID:
21704048
17.

Structures of mGluRs shed light on the challenges of drug development of allosteric modulators.

Bennett KA, Doré AS, Christopher JA, Weiss DR, Marshall FH.

Curr Opin Pharmacol. 2015 Feb;20:1-7. doi: 10.1016/j.coph.2014.09.022. Epub 2014 Oct 17. Review.

PMID:
25462286
18.

Discovery of positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5).

Williams DL Jr, Lindsley CW.

Curr Top Med Chem. 2005;5(9):825-46. Review.

PMID:
16178729
19.

Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment.

Ellaithy A, Younkin J, González-Maeso J, Logothetis DE.

Trends Neurosci. 2015 Aug;38(8):506-16. doi: 10.1016/j.tins.2015.06.002. Epub 2015 Jul 4. Review.

20.

Positive allosteric modulators to peptide GPCRs: a promising class of drugs.

Bartfai T, Wang MW.

Acta Pharmacol Sin. 2013 Jul;34(7):880-5. doi: 10.1038/aps.2013.20. Epub 2013 Apr 29. Review.

Supplemental Content

Support Center